(2S,3R,4R,5S,6R)-2-(7-(4-ethylbenzyl)benzo[d][1,3]dioxol-5-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (2S,3R,4R,5S,6R)-2-(7-(4-ethylbenzyl)benzo[d][1,3]dioxol-5-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
• 英文别名: (2S,3R,4R,5S,6R)-2-[7-[(4-ethylphenyl)methyl]-1,3-benzodioxol-5-yl]-6-(hydroxymethyl)oxane-3,4,5-triol
• 化学式: C₂₂H₂₆O₇
• 分子量: 402.444
• InChiKey: IBBNPEYJJHRIOV-JPVHLGFFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  29
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  109
• 氢给体数：
  4
• 氢受体数：
  7

文献信息

• C-glucoside derivative containing fused phenyl ring or pharmaceutically acceptable salt thereof, process for preparing same, and pharmaceutical composition comprising same
  申请人：Je II Pharmaceutical Co., Ltd.

  公开号：US10752604B2

  公开（公告）日：2020-08-25

  The present disclosure relates to C-glycoside derivatives having a fused phenyl ring or pharmaceutical acceptable salts thereof, a method for preparing the same, a pharmaceutical composition comprising the same, a use thereof and a method for dual inhibition of SGLT1 and SGLT2 using the same. A novel compound of the present disclosure has a dual inhibitory activity against SGLT1 and SGLT2, thus being valuably used as a diabetes therapeutic agent.

  本公开涉及具有融合苯基环的 C-糖苷衍生物或其药物可接受盐、制备方法、包含其的药物组合物、其用途以及使用其对 SGLT1 和 SGLT2 进行双重抑制的方法。本公开的一种新型化合物具有对 SGLT1 和 SGLT2 的双重抑制活性，因此可用作糖尿病治疗剂。
• C-GLUCOSIDE DERIVATIVE CONTAINING FUSED PHENYL RING OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PROCESS FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
  申请人：Jeil Pharmaceutical Co., Ltd.

  公开号：EP3404033B1

  公开（公告）日：2020-08-05
• C-Glucoside Derivative Containing Fused Phenyl Ring or Pharmaceutically Acceptable Salt Thereof, Process for Preparing Same, and Pharmaceutical Composition Comprising Same
  申请人：Je Il Pharmaceutical Co., Ltd.

  公开号：US20190002425A1

  公开（公告）日：2019-01-03

  The present disclosure relates to C-glycoside derivatives having a fused phenyl ring or pharmaceutical acceptable salts thereof, a method for preparing the same, a pharmaceutical composition comprising the same, a use thereof and a method for dual inhibition of SGLT1 and SGLT2 using the same. A novel compound of the present disclosure has a dual inhibitory activity against SGLT1 and SGLT2, thus being valuably used as a diabetes therapeutic agent.